An Open-Label Study On The Effects Of Human Secretin For Injection (CHIROSTIM) On Pancreatic Fluid Composition In Normal Human Volunteer Participants
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: t
View:
• Males or non-pregnant females
• Age 18-80.
• Participants must be in good health based on medical history (ASA Class 3 or below)
• Participants must be willing and able to provide informed consent
• Receiving an endoscopic ultrasound for a non-pancreatic indication
Locations
United States
Minnesota
Mayo Clinic in Rochester
RECRUITING
Rochester
Contact Information
Primary
Liz Lemke
Lemke.Elizabeth@mayo.edu
507-266-3317
Backup
Samuel Han, MD
han.samuel@mayo.edu
Time Frame
Start Date: 2026-03-11
Estimated Completion Date: 2028-03
Participants
Target number of participants: 24
Treatments
Experimental: Healthy Participants
Healthy participants without pancreatic disease who are undergoing an endoscopic ultrasound for a non-pancreatic indication. This arm will be stratified into 3 age groups: 18-35, 35-45, and 46+ years. Participants will be given a standard dose of intravenous human secretin (0.2 mcg/kg) during the endoscopic ultrasound. During this time, pancreatic fluid will be collected at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after secretin administration.
Related Therapeutic Areas
Sponsors
Leads: Mayo Clinic
Collaborators: ChiRhoClin, Inc.